

PIMSH 15: Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center - Avoidance of Overuse

Drug guidance

Denominator:

For multi-drug regimens, select antiemetic therapy based on the drug with the highest emetic risk. For guidance on determining emetic risk, please refer to Table 1, Emetic Risk of Single Intravenous Antineoplastic Agents in Adults (Hesketh et al., 2020, pp. 2787-1288).

Risk Level

Low (10%-30%)

Agent

Aflibercept
Axicabtagene ciloleucel
Belinostat
Blinatumomab
Bortezomib
Brentuximab
Cabazitaxel
Carfilzomib
Catumaxumab
Cetuximab
Cytarabine $\leq 1,000$ mg/m²
Decitabine
Docetaxel
Elotuzumab
Enfortumab vedotin-ejfv
Eribulin
Etoposide
Fluorouracil
Gemcitabine
Gemcitabine ozogamicin
Inotuzumab ozogamicin
Ixabepilone
Methotrexate
Mitomycin
Mitoxantrone
Moxetumomab pasudotox
Nab-paclitaxel
Necitumumab
Nelarabine
Paclitaxel
Panitumumab
Pegylated liposomal doxorubicin
Pemetrexed
Pertuzumab
Tagraxofusp-erzs
Temsilolimus
Tisagenlecleucel
Topotecan
Trastuzumab-emtansine

Minimal (< 10%)	Vinflunine
	Atezolizumab
	Avelumab
	Bevacizumab
	Bleomycin
	Cemiplimab
	2-Chlorodeoxyadenosine
	Cladribine
	Daratumumab
	Durvalumab
	Emapalumab
	Fludarabine
	Ipilimumab
	Nivolumab
	Obinutuzumab
	Ofatumumab
	Pembrolizumab
	Pixantrone
	Polatazumab vedotin
	Pralatrexate
	Ramucirumab
	Rituximab
	Trastuzumab
	Vinblastine
	Vincristine
	Vinorelbine

Numerator:

For the purposes of the measure, the following antiemetics would meet the measure:

- Antiemetics administered on the same day as cycle 1 day 1 of the therapy OR
- Any new or refill prescription order of antiemetics on the same day as cycle 1 day 1 of the therapy or within 89 days prior to cycle 1 day 1 of the therapy OR
- Any record of antiemetics as active on the medication list within 90 days prior to cycle 1 day 1 of the therapy

This version of the eCQM uses QDM version 5.6. Please refer to the eCQI resource center (<https://ecqi.healthit.gov/qdm>) for more information on the QDM.